首页 > 最新文献

DARU Journal of Pharmaceutical Sciences最新文献

英文 中文
Multi-functionalization of reduced graphene oxide nanosheets for tumor theragnosis: Synthesis, characterization, enzyme assay, in-silico study, radiolabeling and in vivo targeting evaluation 用于肿瘤诊断的还原氧化石墨烯纳米片的多功能化:合成、表征、酶测定、硅内研究、放射性标记和体内靶向评估
IF 3.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-11 DOI: 10.1007/s40199-023-00487-7
Tamer M. Sakr, Mohammed F. Elsabagh, Hend Fayez, Mona O. Sarhan, Yasmin M. Syam, Manal M. Anwar, Mohammed A. Motaleb, Wafaa A. Zaghary

Background

In this study, a combination of nanotechnology, organic synthesis and radiochemistry were utilized in order to design an efficient nano-system conjugated with a suitable radionuclide and an antitumor agent for possible application as tumor theragnostic agent.

Method

Four novel compounds (3 and 4a-c) bearing tetrahydroquinazoline-7-sulfonohydrazide or 1,2,3,4-tetrahydroquinazoline-7-sulfonamide scaffold were designed. Then, docking study predicted that the compounds can be considered as potential inhibitors for PARP-1. Following that; the four compounds were synthesized and properly characterized using 1HNMR, 13CNMR, IR and Mass spectroscopy. The cytotoxic effect of the four compounds was evaluated against breast cancer cell line (MDA-MB-436), where compound 3 showed the most promising cytotoxic effect. The inhibitory effect of the four compounds was evaluated in vitro against PARP-1.

Result

Carboxylated graphene oxide nanosheets (NGO-COOH) were synthesized by a modified Hummer's method and has size of range 40 nm. The NGO-COOH nanosheets were proven to be safe and biocompatible when tested in vitro against normal human lung fibroblast cells (MRC-5). The prepared NGO-COOH nanosheets were conjugated with compound 3 then radiolabeled with 99mTc to yield 99mTc-NGO-COOH-3 with a radiochemical yield of 98.5.0 ± 0.5%. 99mTc-NGO-COOH-3 was injected intravenously in solid tumor bearing mice to study the degree of localization of the nano-system at tumor tissue. The results of the study revealed, excellent localization and retention of the designed nano-system at tumor tissues with targeting ratio of 9.0.

Conclusion

Stirred a new candidate tumor theragnostic agent that is safe, selective and stable.

Graphical abstract

背景本研究将纳米技术、有机合成和放射化学结合起来,旨在设计一种与合适的放射性核素和抗肿瘤药物共轭的高效纳米系统,以作为肿瘤治疗剂。方法设计了四种具有四氢喹唑啉-7-磺酰肼或 1,2,3,4- 四氢喹唑啉-7-磺酰胺支架的新型化合物(3 和 4a-c)。然后,对接研究预测这些化合物可被视为 PARP-1 的潜在抑制剂。随后,合成了这四个化合物,并使用 1HNMR、13CNMR、红外光谱和质谱对其进行了表征。评估了这四种化合物对乳腺癌细胞系(MDA-MB-436)的细胞毒性作用,其中化合物 3 的细胞毒性作用最为显著。结果羧基氧化石墨烯纳米片(NGO-COOH)采用改良的 Hummer 方法合成,尺寸为 40 nm。在对正常人肺成纤维细胞(MRC-5)进行体外测试时,NGO-COOH 纳米片被证明具有安全性和生物相容性。制备出的NGO-COOH纳米片与化合物3共轭,然后用99m锝进行放射标记,得到99m锝-NGO-COOH-3,放射化学产率为98.5.0 ± 0.5%。将 99mTc-NGO-COOH-3 静脉注射到实体瘤小鼠体内,研究纳米系统在肿瘤组织中的定位程度。研究结果表明,所设计的纳米系统在肿瘤组织中的定位和保留效果极佳,靶向率达到 9.0。
{"title":"Multi-functionalization of reduced graphene oxide nanosheets for tumor theragnosis: Synthesis, characterization, enzyme assay, in-silico study, radiolabeling and in vivo targeting evaluation","authors":"Tamer M. Sakr, Mohammed F. Elsabagh, Hend Fayez, Mona O. Sarhan, Yasmin M. Syam, Manal M. Anwar, Mohammed A. Motaleb, Wafaa A. Zaghary","doi":"10.1007/s40199-023-00487-7","DOIUrl":"https://doi.org/10.1007/s40199-023-00487-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>In this study, a combination of nanotechnology, organic synthesis and radiochemistry were utilized in order to design an efficient nano-system conjugated with a suitable radionuclide and an antitumor agent for possible application as tumor theragnostic agent.</p><h3 data-test=\"abstract-sub-heading\">Method</h3><p>Four novel compounds (3 and 4a-c) bearing tetrahydroquinazoline-7-sulfonohydrazide or 1,2,3,4-tetrahydroquinazoline-7-sulfonamide scaffold were designed. Then, docking study predicted that the compounds can be considered as potential inhibitors for PARP-1. Following that; the four compounds were synthesized and properly characterized using <sup><i>1</i></sup><i>H</i>NMR, <sup><i>13</i></sup><i>C</i>NMR, IR and Mass spectroscopy. The cytotoxic effect of the four compounds was evaluated against breast cancer cell line (MDA-MB-436), where compound 3 showed the most promising cytotoxic effect. The inhibitory effect of the four compounds was evaluated in vitro against PARP-1.</p><h3 data-test=\"abstract-sub-heading\">Result</h3><p>Carboxylated graphene oxide nanosheets (NGO-COOH) were synthesized by a modified Hummer's method and has size of range 40 nm. The NGO-COOH nanosheets were proven to be safe and biocompatible when tested in vitro against normal human lung fibroblast cells (MRC-5). The prepared NGO-COOH nanosheets were conjugated with compound 3 then radiolabeled with <sup>99m</sup>Tc to yield <sup>99m</sup>Tc-NGO-COOH-3 with a radiochemical yield of 98.5.0 ± 0.5%. <sup>99m</sup>Tc-NGO-COOH-3 was injected intravenously in solid tumor bearing mice to study the degree of localization of the nano-system at tumor tissue. The results of the study revealed, excellent localization and retention of the designed nano-system at tumor tissues with targeting ratio of 9.0.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Stirred a new candidate tumor theragnostic agent that is safe, selective and stable.</p><h3 data-test=\"abstract-sub-heading\">Graphical abstract</h3>\u0000","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"3 4 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138566855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying natural products for gastric cancer treatment through pharmacophore creation, 3D QSAR, virtual screening, and molecular dynamics studies. 通过药效团创建、3D QSAR、虚拟筛选和分子动力学研究鉴定用于治疗癌症的天然产物。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-01 Epub Date: 2023-09-21 DOI: 10.1007/s40199-023-00480-0
Zeinab Jalali, Samad Nejad Ebrahimi, Hassan Rezadoost

Background: Gastric cancer (GC) is known as the fourth leading cause of cancer-related death and the fifth major cancer in the world, and this is a serious threat to general health all over the world. The lack of early detection markers results in a belated diagnosis, i.e. the final stages, which could be associated with the ineffectiveness of the treatment strategies, and naturally, it leads to poor prognosis. Even though a variety of treatments have been developed, there is a trend of studying traditional medicinal plants, due to the worrying side effect of drugs available in the market.

Methods: In this study, pharmacophore generation and 3D-QSAR model were created using 50 compounds with anti-gastric cancer activity (with IC50 had been reported in the previous studies).

Results: Based on three of the best pharmacophoric hypotheses, virtual screening was performed to discover the top anti-gastric cancer compounds from a database of 183,885 compounds. The selected compounds were used for molecular docking with three protein receptors 7BKG, 4F5B, and 4ZT1 to investigate the intermolecular interactions between these ligands and receptors. Finally, 21 lead compounds with the highest amount of docking score ranging from - 13.366 to -6.404 kcal/mol were selected, and then the ADME/Tox properties of these compounds were calculated. All these compounds have a fitness score above 1.8, a molecular weight of less than 500 g/mol, hydrogen bond donors up to 3, hydrogen bond acceptors up to 8.50, and logP of 1.013 to 4.174. Finally, molecular dynamic simulations for top-scoring ligand-receptor complexes were investigated.

Conclusion: These selected lead compounds have the most anti-gastric cancer effects among the 183,885 compounds in the database. Therefore, lead compounds might be considered for gastric cancer therapy in future studies.

背景:癌症是世界上第四大癌症死亡原因和第五大癌症,严重威胁着全世界的健康。缺乏早期检测标志物会导致诊断滞后,即最后阶段,这可能与治疗策略的无效性有关,自然会导致预后不良。尽管已经开发出了各种治疗方法,但由于市场上可用药物的副作用令人担忧,仍有研究传统药用植物的趋势。方法:在本研究中,使用50种具有抗胃癌癌症活性的化合物创建药效团生成和3D-QSAR模型(IC50已在先前的研究中报道)。所选择的化合物用于与三种蛋白质受体7BKG、4F5B和4ZT1的分子对接,以研究这些配体和受体之间的分子间相互作用。最后,21种先导化合物的对接得分最高,范围从- 选择13.366至-6.404 kcal/mol,然后计算这些化合物的ADME/Tox性质。所有这些化合物的适合度得分都在1.8以上,分子量小于500g/mol,氢键供体高达3,氢键受体高达8.50,logP为1.013至4.174。最后,研究了得分最高的配体-受体复合物的分子动力学模拟。结论:在数据库中的183885个化合物中,筛选出的这些先导化合物具有最大的抗癌症作用。因此,在未来的研究中,铅化合物可能被考虑用于癌症的治疗。
{"title":"Identifying natural products for gastric cancer treatment through pharmacophore creation, 3D QSAR, virtual screening, and molecular dynamics studies.","authors":"Zeinab Jalali, Samad Nejad Ebrahimi, Hassan Rezadoost","doi":"10.1007/s40199-023-00480-0","DOIUrl":"10.1007/s40199-023-00480-0","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is known as the fourth leading cause of cancer-related death and the fifth major cancer in the world, and this is a serious threat to general health all over the world. The lack of early detection markers results in a belated diagnosis, i.e. the final stages, which could be associated with the ineffectiveness of the treatment strategies, and naturally, it leads to poor prognosis. Even though a variety of treatments have been developed, there is a trend of studying traditional medicinal plants, due to the worrying side effect of drugs available in the market.</p><p><strong>Methods: </strong>In this study, pharmacophore generation and 3D-QSAR model were created using 50 compounds with anti-gastric cancer activity (with IC<sub>50</sub> had been reported in the previous studies).</p><p><strong>Results: </strong>Based on three of the best pharmacophoric hypotheses, virtual screening was performed to discover the top anti-gastric cancer compounds from a database of 183,885 compounds. The selected compounds were used for molecular docking with three protein receptors 7BKG, 4F5B, and 4ZT1 to investigate the intermolecular interactions between these ligands and receptors. Finally, 21 lead compounds with the highest amount of docking score ranging from - 13.366 to -6.404 kcal/mol were selected, and then the ADME/Tox properties of these compounds were calculated. All these compounds have a fitness score above 1.8, a molecular weight of less than 500 g/mol, hydrogen bond donors up to 3, hydrogen bond acceptors up to 8.50, and logP of 1.013 to 4.174. Finally, molecular dynamic simulations for top-scoring ligand-receptor complexes were investigated.</p><p><strong>Conclusion: </strong>These selected lead compounds have the most anti-gastric cancer effects among the 183,885 compounds in the database. Therefore, lead compounds might be considered for gastric cancer therapy in future studies.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"243-258"},"PeriodicalIF":2.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41111493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilization patterns of cardiovascular medications in patients with diabetes mellitus; a retrospective cross-sectional study, 2013-17. 糖尿病患者心血管药物的使用模式;一项回顾性横断面研究,2013-17。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-01 Epub Date: 2023-10-17 DOI: 10.1007/s40199-023-00481-z
Negin Hatami, Mohammad-Reza Malekpour, Farshad Farzadfar, Meysam Seyedifar, Fatemeh Soleymani

Background: Diabetes Mellitus (DM) is a prominent health care issue worldwide. One of the most prevalent comorbidities of DM is cardiovascular disease (CVD). The objective of this study was to assess the utilization patterns of cardiovascular medications in patients with DM in Iran from 2013 to 2017.

Methods: This retrospective cross-sectional study was undertaken using prescription claims data from 2013 to 2017 in Iran. Epidemiological data elements used in this study were obtained from the Global Burden of Disease (GBD) 2019 study. In addition, data on total medication sales were obtained from the national regulatory authority database. The data on medication utilization were analyzed according to the Anatomical Therapeutic Chemical Classification (ATC) /Defined Daily Doses (DDD) international system.

Results: Based on the findings, Acetylsalicylic acid was the mainstay of treatment with a utilization rate of 191.7 DDD/ patient/ year in 2017, followed by Atorvastatin with 170.0 and Losartan with 115.1. Although there was an increasing trend in the utilization rate of the medications, the rate of Atenolol and Enalapril was constantly declining during the 2013-17 period. On the other hand, Valsartan and Metoprolol were attracting attention. Almost all medication utilization rates increased from the 30-39 age group up to the 80 + age group. Females had a higher utilization rate in each age group during the whole study period.

Conclusion: The present study reflects that medication utilization patterns were rational, according to the standard treatment guidelines. Utilization patterns of medications that are recommended for both prevention and treatment of CVD in diabetes were observed to be the highest. Implementation of further policies is needed to minimize cardiovascular complications of diabetes.

背景:糖尿病(DM)是世界范围内一个突出的医疗保健问题。糖尿病最常见的合并症之一是心血管疾病(CVD)。本研究的目的是评估2013年至2017年伊朗糖尿病患者心血管药物的使用模式。方法:本回顾性横断面研究使用2013年至17年伊朗的处方索赔数据。本研究中使用的流行病学数据元素来自2019年全球疾病负担(GBD)研究。此外,药品销售总额数据来自国家监管机构数据库。根据解剖学治疗化学分类(ATC)/限定日剂量(DDD)国际系统分析药物使用数据。结果:根据研究结果,乙酰水杨酸是治疗的主要药物,2017年使用率为191.7 DDD/患者/年,其次是阿托伐他汀170.0和氯沙坦115.1。尽管药物使用率有上升趋势,但在2013-17年期间,阿替洛尔和依那普利的使用率一直在下降。另一方面,缬沙坦和美托洛尔引起了人们的注意。从30-39岁到80岁,几乎所有的药物使用率都有所提高 + 年龄组。在整个研究期间,每个年龄组的女性使用率都较高。结论:本研究反映出药物利用模式是合理的,符合标准的治疗指南。建议用于预防和治疗糖尿病CVD的药物使用模式最高。需要实施进一步的政策,以最大限度地减少糖尿病的心血管并发症。
{"title":"Utilization patterns of cardiovascular medications in patients with diabetes mellitus; a retrospective cross-sectional study, 2013-17.","authors":"Negin Hatami, Mohammad-Reza Malekpour, Farshad Farzadfar, Meysam Seyedifar, Fatemeh Soleymani","doi":"10.1007/s40199-023-00481-z","DOIUrl":"10.1007/s40199-023-00481-z","url":null,"abstract":"<p><strong>Background: </strong>Diabetes Mellitus (DM) is a prominent health care issue worldwide. One of the most prevalent comorbidities of DM is cardiovascular disease (CVD). The objective of this study was to assess the utilization patterns of cardiovascular medications in patients with DM in Iran from 2013 to 2017.</p><p><strong>Methods: </strong>This retrospective cross-sectional study was undertaken using prescription claims data from 2013 to 2017 in Iran. Epidemiological data elements used in this study were obtained from the Global Burden of Disease (GBD) 2019 study. In addition, data on total medication sales were obtained from the national regulatory authority database. The data on medication utilization were analyzed according to the Anatomical Therapeutic Chemical Classification (ATC) /Defined Daily Doses (DDD) international system.</p><p><strong>Results: </strong>Based on the findings, Acetylsalicylic acid was the mainstay of treatment with a utilization rate of 191.7 DDD/ patient/ year in 2017, followed by Atorvastatin with 170.0 and Losartan with 115.1. Although there was an increasing trend in the utilization rate of the medications, the rate of Atenolol and Enalapril was constantly declining during the 2013-17 period. On the other hand, Valsartan and Metoprolol were attracting attention. Almost all medication utilization rates increased from the 30-39 age group up to the 80 + age group. Females had a higher utilization rate in each age group during the whole study period.</p><p><strong>Conclusion: </strong>The present study reflects that medication utilization patterns were rational, according to the standard treatment guidelines. Utilization patterns of medications that are recommended for both prevention and treatment of CVD in diabetes were observed to be the highest. Implementation of further policies is needed to minimize cardiovascular complications of diabetes.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"259-266"},"PeriodicalIF":2.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41233115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vactosertib potently improves anti-tumor properties of 5-FU for colon cancer. Vactosertib能有效改善5-FU对结肠癌的抗肿瘤作用。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-01 Epub Date: 2023-09-23 DOI: 10.1007/s40199-023-00474-y
Maryam Moradi Binabaj, Fereshteh Asgharzadeh, Farzad Rahmani, Abdulridha Mohammed Al-Asady, Milad Hashemzehi, Atena Soleimani, Amir Avan, Saeedeh Mehraban, Elnaz Ghorbani, Mikhail Ryzhikov, Majid Khazaei, Seyed Mahdi Hassanian

Background: Several studies have shown that the TGF-β signaling pathway plays a critical role in colorectal cancer (CRC) pathogenesis. The aim of the current study is to investigate the therapeutic potential of Vactosertib (EW-7197), a selective inhibitor of TGF-β receptor type I, either alone or in combination with the standard first-line chemotherapeutic treatment, 5-Fluorouracil (5-FU), in CRC progression in both cellular and animal models.

Methods: Real-Time PCR, Zymography, enzyme-linked immunosorbent assay (ELISA), Hematoxylin and Eosin (H&E) tissue staining, and Flow cytometry techniques were applied to determine the anti-tumor properties of this novel TGF-β inhibitor in in vitro (CT-26 cell line) and in vivo (inbred BALB/C mice) samples.

Results: Our findings showed that Vactosertib decreased cell proliferation and induced spheroid shrinkage. Moreover, this inhibitor suppressed the cell cycle and its administration either alone or in combination with 5-FU induced apoptosis by regulating the expression of p53 and BAX proteins. It also improved 5-FU anti-cancer effects by decreasing the tumor volume and weight, increasing tumor necrosis, and regulating tumor fibrosis and inflammation in an animal model. Vactosertib also enhanced the inhibitory effect of 5-FU on invasive behavior of CRC cells by upregulating the expression of E-cadherin and inhibiting MMP-9 enzymatic activity.

Conclusion: This study demonstrating the potent anti-tumor effects of Vactosertib against CRC progression. Our results clearly suggest that this inhibitor could be a promising agent reducing CRC tumor progression when administered either alone or in combination with standard treatment in CRC patients.

背景:多项研究表明,TGF-β信号通路在癌症(CRC)的发病机制中起着关键作用。本研究的目的是研究Vactosertib(EW-7197),一种I型TGF-β受体的选择性抑制剂,单独或与标准一线化疗药物5-氟尿嘧啶(5-FU)联合,在细胞和动物模型中对CRC进展的治疗潜力。方法:应用实时PCR、酶联免疫吸附试验(ELISA)、苏木精和Eosin(H&E)组织染色以及流式细胞术技术,在体外(CT-26细胞系)和体内(近交系BALB/C小鼠)样品中测定这种新型TGF-β抑制剂的抗肿瘤特性。结果:我们的研究结果表明,Vactosertib降低了细胞增殖并诱导了球体收缩。此外,该抑制剂通过调节p53和BAX蛋白的表达来抑制细胞周期及其单独或与5-FU联合给药诱导的细胞凋亡。在动物模型中,它还通过降低肿瘤体积和重量、增加肿瘤坏死以及调节肿瘤纤维化和炎症来改善5-FU的抗癌效果。Vactosertib还通过上调E-钙粘蛋白的表达和抑制MMP-9酶活性来增强5-FU对CRC细胞侵袭行为的抑制作用。结论:本研究证明了Vactosertib对CRC进展的有效抗肿瘤作用。我们的研究结果清楚地表明,当单独给药或与CRC患者的标准治疗联合给药时,这种抑制剂可能是一种有前途的减少CRC肿瘤进展的药物。
{"title":"Vactosertib potently improves anti-tumor properties of 5-FU for colon cancer.","authors":"Maryam Moradi Binabaj, Fereshteh Asgharzadeh, Farzad Rahmani, Abdulridha Mohammed Al-Asady, Milad Hashemzehi, Atena Soleimani, Amir Avan, Saeedeh Mehraban, Elnaz Ghorbani, Mikhail Ryzhikov, Majid Khazaei, Seyed Mahdi Hassanian","doi":"10.1007/s40199-023-00474-y","DOIUrl":"10.1007/s40199-023-00474-y","url":null,"abstract":"<p><strong>Background: </strong>Several studies have shown that the TGF-β signaling pathway plays a critical role in colorectal cancer (CRC) pathogenesis. The aim of the current study is to investigate the therapeutic potential of Vactosertib (EW-7197), a selective inhibitor of TGF-β receptor type I, either alone or in combination with the standard first-line chemotherapeutic treatment, 5-Fluorouracil (5-FU), in CRC progression in both cellular and animal models.</p><p><strong>Methods: </strong>Real-Time PCR, Zymography, enzyme-linked immunosorbent assay (ELISA), Hematoxylin and Eosin (H&E) tissue staining, and Flow cytometry techniques were applied to determine the anti-tumor properties of this novel TGF-β inhibitor in in vitro (CT-26 cell line) and in vivo (inbred BALB/C mice) samples.</p><p><strong>Results: </strong>Our findings showed that Vactosertib decreased cell proliferation and induced spheroid shrinkage. Moreover, this inhibitor suppressed the cell cycle and its administration either alone or in combination with 5-FU induced apoptosis by regulating the expression of p53 and BAX proteins. It also improved 5-FU anti-cancer effects by decreasing the tumor volume and weight, increasing tumor necrosis, and regulating tumor fibrosis and inflammation in an animal model. Vactosertib also enhanced the inhibitory effect of 5-FU on invasive behavior of CRC cells by upregulating the expression of E-cadherin and inhibiting MMP-9 enzymatic activity.</p><p><strong>Conclusion: </strong>This study demonstrating the potent anti-tumor effects of Vactosertib against CRC progression. Our results clearly suggest that this inhibitor could be a promising agent reducing CRC tumor progression when administered either alone or in combination with standard treatment in CRC patients.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"193-203"},"PeriodicalIF":2.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41101911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design, synthesis and docking study of Vortioxetine derivatives as a SARS-CoV-2 main protease inhibitor Vortioxetine衍生物作为SARS-CoV-2主要蛋白酶抑制剂的设计、合成及对接研究
IF 3.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-05-04 DOI: 10.1007/s40199-022-00441-z
Hemant Suryavanshi, Raju D Chaudhari, Vishakha S. Patil, S. Majumdar, S. Debnath, Goutam Biswas
{"title":"Design, synthesis and docking study of Vortioxetine derivatives as a SARS-CoV-2 main protease inhibitor","authors":"Hemant Suryavanshi, Raju D Chaudhari, Vishakha S. Patil, S. Majumdar, S. Debnath, Goutam Biswas","doi":"10.1007/s40199-022-00441-z","DOIUrl":"https://doi.org/10.1007/s40199-022-00441-z","url":null,"abstract":"","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"9 1","pages":"139 - 152"},"PeriodicalIF":3.6,"publicationDate":"2022-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83078621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Facile electrochemical preparation of overoxidizedpolypyrrole/RGO composite for ds-DNA immobilization: a novel signal amplified sensing platform for electrochemical determination of chlorpheniramine 电化学制备用于ds-DNA固定的过氧化聚吡咯/氧化石墨烯复合材料:一种新的电化学测定氯苯那敏的信号放大传感平台
IF 3.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2019-12-05 DOI: 10.1007/s40199-019-00314-y
K. Moulaee, M. Ganjali, P. Norouzi, H. Beitollahi
{"title":"Facile electrochemical preparation of overoxidizedpolypyrrole/RGO composite for ds-DNA immobilization: a novel signal amplified sensing platform for electrochemical determination of chlorpheniramine","authors":"K. Moulaee, M. Ganjali, P. Norouzi, H. Beitollahi","doi":"10.1007/s40199-019-00314-y","DOIUrl":"https://doi.org/10.1007/s40199-019-00314-y","url":null,"abstract":"","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"695 1","pages":"57 - 64"},"PeriodicalIF":3.6,"publicationDate":"2019-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85320227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
The effect of metal salts on aerosol performance of spray dried carrier-free formulations of levofloxacin 金属盐对左氧氟沙星无载体喷雾干燥制剂气溶胶性能的影响
IF 3.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2019-12-05 DOI: 10.1007/s40199-019-00317-9
A. Barazesh, K. Gilani, M. Rouini, M. Barghi
{"title":"The effect of metal salts on aerosol performance of spray dried carrier-free formulations of levofloxacin","authors":"A. Barazesh, K. Gilani, M. Rouini, M. Barghi","doi":"10.1007/s40199-019-00317-9","DOIUrl":"https://doi.org/10.1007/s40199-019-00317-9","url":null,"abstract":"","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"74 1","pages":"75 - 85"},"PeriodicalIF":3.6,"publicationDate":"2019-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74645523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Alpha-mangostin decreased cellular senescence in human umbilical vein endothelial cells α -山竹苷延缓人脐静脉内皮细胞衰老
IF 3.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2019-12-03 DOI: 10.1007/s40199-019-00305-z
Hourieh Tousian, B. Razavi, H. Hosseinzadeh
{"title":"Alpha-mangostin decreased cellular senescence in human umbilical vein endothelial cells","authors":"Hourieh Tousian, B. Razavi, H. Hosseinzadeh","doi":"10.1007/s40199-019-00305-z","DOIUrl":"https://doi.org/10.1007/s40199-019-00305-z","url":null,"abstract":"","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"119 1","pages":"45 - 55"},"PeriodicalIF":3.6,"publicationDate":"2019-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77951246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Acetaminophen poisoning-induced heart injury: a case-based review. 对乙酰氨基酚中毒引起的心脏损伤:基于病例的综述。
IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2019-12-01 Epub Date: 2019-11-11 DOI: 10.1007/s40199-019-00307-x
Fatemeh KhabazianZadeh, Tooba Kazemi, Samaneh Nakhaee, Patrick C Ng, Omid Mehrpour

Purpose: Acetaminophen (Paracetamol, APAP) poisoning is frequently implicated in self-harm. Cases of acetaminophen-associated cardiotoxicity are rare in relation to the number of patients with acetaminophen poisoning. A review of acetaminophen cardiotoxicity in 1996 concluded that there was no decisive evidence demonstrating that acetaminophen overdose has a cardiotoxic effect. This review study aimed to determine whether acetaminophen could induce heart injury.

Methods: We searched for keywords of acetaminophen, paracetamol, cardiotoxicity, heart injury, heart damage, myocarditis, pericarditis, myocardial infarction, and myocardial ischemia in Web of Science, PubMed, Scopus, Embase, Google Scholar, and Persian databases. The search included articles published from January 1950 to October 2018 with no language restrictions.

Results: The search yielded 64 citations in English; 36 of the articles were excluded as they were not relevant; 5 articles were excluded since they were duplicates, leaving 23 articles. Full-text articles of the 23 citations were obtained and reviewed. Myocardial infarction, heart dysfunction and failure, cardiac arrhythmias, pericarditis, heart cell necrosis, and sudden cardiac death were reported in acetaminophen overdose.

Conclusions: Ddysrhythmias, heart failure, and various other cardiac effects could occur following acetaminophen induced hepatic failure. However, the evidence for direct injury on cardiac tissue is weak. Graphical abstract Potential mechanisms for cardiotoxicity of acetaminophen.

目的:对乙酰氨基酚(APAP)中毒常与自身伤害有关。与对乙酰氨基酚中毒患者数量相关的对乙酰氨基苯酚相关心脏毒性病例很少。1996年对对乙酰氨基酚心脏毒性的审查得出结论,没有决定性的证据表明过量服用乙酰氨基酚具有心脏毒性作用。本综述研究旨在确定对乙酰氨基酚是否会导致心脏损伤。方法:我们在Web of Science、PubMed、Scopus、Embase、Google Scholar和Persian数据库中搜索对乙酰氨基酚、扑热息痛、心脏毒性、心脏损伤、心脏损害、心肌炎、心包炎、心肌梗死和心肌缺血的关键词。搜索包括1950年1月至2018年10月发表的文章,没有语言限制。结果:检索得到64篇英文引文;其中36条因不相关而被排除在外;5篇文章被排除在外,因为它们是重复的,剩下23篇文章。获得并审查了23篇引文的全文文章。对乙酰氨基酚过量引起心肌梗死、心脏功能障碍和衰竭、心律失常、心包炎、心脏细胞坏死和心源性猝死。结论:对乙酰氨基酚诱导的肝功能衰竭可能会出现心律失常、心力衰竭和其他各种心脏影响。然而,直接损伤心脏组织的证据并不充分。图形摘要对乙酰氨基酚心脏毒性的潜在机制。
{"title":"Acetaminophen poisoning-induced heart injury: a case-based review.","authors":"Fatemeh KhabazianZadeh, Tooba Kazemi, Samaneh Nakhaee, Patrick C Ng, Omid Mehrpour","doi":"10.1007/s40199-019-00307-x","DOIUrl":"10.1007/s40199-019-00307-x","url":null,"abstract":"<p><strong>Purpose: </strong>Acetaminophen (Paracetamol, APAP) poisoning is frequently implicated in self-harm. Cases of acetaminophen-associated cardiotoxicity are rare in relation to the number of patients with acetaminophen poisoning. A review of acetaminophen cardiotoxicity in 1996 concluded that there was no decisive evidence demonstrating that acetaminophen overdose has a cardiotoxic effect. This review study aimed to determine whether acetaminophen could induce heart injury.</p><p><strong>Methods: </strong>We searched for keywords of acetaminophen, paracetamol, cardiotoxicity, heart injury, heart damage, myocarditis, pericarditis, myocardial infarction, and myocardial ischemia in Web of Science, PubMed, Scopus, Embase, Google Scholar, and Persian databases. The search included articles published from January 1950 to October 2018 with no language restrictions.</p><p><strong>Results: </strong>The search yielded 64 citations in English; 36 of the articles were excluded as they were not relevant; 5 articles were excluded since they were duplicates, leaving 23 articles. Full-text articles of the 23 citations were obtained and reviewed. Myocardial infarction, heart dysfunction and failure, cardiac arrhythmias, pericarditis, heart cell necrosis, and sudden cardiac death were reported in acetaminophen overdose.</p><p><strong>Conclusions: </strong>Ddysrhythmias, heart failure, and various other cardiac effects could occur following acetaminophen induced hepatic failure. However, the evidence for direct injury on cardiac tissue is weak. Graphical abstract Potential mechanisms for cardiotoxicity of acetaminophen.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"27 2","pages":"839-851"},"PeriodicalIF":2.5,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895290/pdf/40199_2019_Article_307.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49675387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial. 口服骨化三醇对自体干细胞移植后造血恢复和存活的影响:一项随机临床试验。
IF 3.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2019-12-01 Epub Date: 2019-11-11 DOI: 10.1007/s40199-019-00306-y
Kosar Raoufinejad, Ahmad Reza Shamshiri, Shahrzad Pezeshki, Bahram Chahardouli, Molouk Hadjibabaie, Zahra Jahangard-Rafsanjani, Kheirollah Gholami, Mehdi Rajabi, Mohammad Vaezi

Background: Calcitriol, the active metabolite of vitamin D, is an essential regulator in the hematopoiesis and immunity. However, knowledge revealing its influence on the immune and hematologic reconstitution after hematopoietic stem cell transplantation (HSCT) in clinical trials is very limited.

Objectives: The effects of calcitriol on short-term and long-term hematopoietic recovery, relapse-free survival (RFS) and overall survival (OS) in multiple myeloma, Hodgkin's and non-Hodgkin's lymphoma following autologous peripheral blood HSCT were assessed.

Methods: Eighty patients (age: 18-68 years) in complete remission were allocated 1:1 to two groups by balanced block randomization. Calcitriol 0.25 μg or placebo capsule was administered three times daily from transplantation to day 30. Absolute neutrophil count (ANC), absolute lymphocyte count (ALC), and platelet count (PC) were determined daily from transplantation to day 30. White blood cell count (WBC), PC, and hemoglobin concentration (HC) of days 180 and 365 were extracted from clinic files. A thorough examination for oral mucositis (OM) was completed daily during hospital stay. Adverse drug reactions (ADRs) as well as two-year RFS and OS were evaluated.

Results: Median time to ANC engraftment (≥0.5 × 103/μl: 10.0 vs. 11.0 days; P = 0.98) and PC engraftment (≥20.0 × 103/μl: both 14.0 days; P = 0.58) was similar between groups. However, the median time to ALC recovery was significantly shorter in the calcitriol group (≥0.5 × 103/μl: 13.0 vs. 20.0 days; P < 0.001). Moreover, ALC recovery rates on day 15 (≥0.5 × 103/μl: 82.1% vs. 42.5%; P < 0.001) and on day 30 (≥1.0 × 103/μl: 91.7% vs. 57.5%; P = 0.001) was significantly higher with calcitriol. WBC, PC, and HC on days 180 and 365 were not significantly different between groups. None of the OM indices were modulated by calcitriol. All the ADRs were non-serious and mild, possibly or unlikely related to the intervention. In a median of 29 months follow-up, RFS was significantly better in the calcitriol group (77.0%, SE = 7.0% vs. 59.0%, SE = 8.0%; P = 0.03), albeit the OS was not affected (87.0%, SE = 5.0% vs. 92.0%, SE = 4.0%; P = 0.72).

Conclusion: Calcitriol could improve ALC recovery and RFS as a safe option post-HSCT. Graphical abstract Oral calcitriol 0.25 µg three times daily from transplantation to day 30 improved lymphocytes recovery and two-year relapse-free survival as a safe option in 80 patients of autologous hematopoietic stem cell transplantation in comparison with placebo.

背景:钙三醇是维生素D的活性代谢产物,是造血和免疫的重要调节因子。然而,在临床试验中揭示其对造血干细胞移植(HSCT)后免疫和血液重建影响的知识非常有限。目的:评价骨化三醇对自体外周血造血干细胞移植后多发性骨髓瘤、霍奇金淋巴瘤和非霍奇金淋巴瘤的短期和长期造血恢复、无复发生存率(RFS)和总生存率(OS)的影响。方法:80例完全缓解的患者(年龄:18-68岁)通过平衡分组随机分为两组。Calcitriol 0.25μg或安慰剂胶囊从移植至第30天每天给药三次。从移植到第30天,每天测定中性粒细胞绝对计数(ANC)、淋巴细胞绝对计数(ALC)和血小板计数(PC)。从临床文件中提取第180天和第365天的白细胞计数(WBC)、PC和血红蛋白浓度(HC)。住院期间每天对口腔粘膜炎(OM)进行彻底检查。评估药物不良反应(ADR)以及两年RFS和OS。结果:ANC植入的中位时间(≥0.5 × 103/μl:10.0天对11.0天;P = 0.98)和PC植入(≥20.0 × 103/μl:均为14.0天;P = 0.58)相似。然而,骨化三醇组ALC恢复的中位时间明显更短(≥0.5 × 103/μl:13.0天对20.0天;P 3/μl:82.1%对42.5%;P 3/μl:91.7%对57.5%;P = 0.001)显著高于骨化三醇。第180天和第365天的WBC、PC和HC在各组之间没有显著差异。OM指数均未受到骨化三醇的调节。所有ADR均为非严重和轻度,可能或不太可能与干预有关。在中位29个月的随访中,骨化三醇组的RFS显著改善(77.0%,SE = 7.0%对59.0%,SE = 8.0%;P = 0.03),尽管OS没有受到影响(87.0%,SE = 5.0%对92.0%,SE = 4.0%;P = 结论:Calcitriol可改善ALC的恢复,RFS是HSCT后的安全选择。图形摘要与安慰剂相比,从移植到第30天,每天三次口服0.25µg骨化三醇,作为80名自体造血干细胞移植患者的安全选择,可改善淋巴细胞恢复和两年无复发生存率。
{"title":"Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial.","authors":"Kosar Raoufinejad,&nbsp;Ahmad Reza Shamshiri,&nbsp;Shahrzad Pezeshki,&nbsp;Bahram Chahardouli,&nbsp;Molouk Hadjibabaie,&nbsp;Zahra Jahangard-Rafsanjani,&nbsp;Kheirollah Gholami,&nbsp;Mehdi Rajabi,&nbsp;Mohammad Vaezi","doi":"10.1007/s40199-019-00306-y","DOIUrl":"https://doi.org/10.1007/s40199-019-00306-y","url":null,"abstract":"<p><strong>Background: </strong>Calcitriol, the active metabolite of vitamin D, is an essential regulator in the hematopoiesis and immunity. However, knowledge revealing its influence on the immune and hematologic reconstitution after hematopoietic stem cell transplantation (HSCT) in clinical trials is very limited.</p><p><strong>Objectives: </strong>The effects of calcitriol on short-term and long-term hematopoietic recovery, relapse-free survival (RFS) and overall survival (OS) in multiple myeloma, Hodgkin's and non-Hodgkin's lymphoma following autologous peripheral blood HSCT were assessed.</p><p><strong>Methods: </strong>Eighty patients (age: 18-68 years) in complete remission were allocated 1:1 to two groups by balanced block randomization. Calcitriol 0.25 μg or placebo capsule was administered three times daily from transplantation to day 30. Absolute neutrophil count (ANC), absolute lymphocyte count (ALC), and platelet count (PC) were determined daily from transplantation to day 30. White blood cell count (WBC), PC, and hemoglobin concentration (HC) of days 180 and 365 were extracted from clinic files. A thorough examination for oral mucositis (OM) was completed daily during hospital stay. Adverse drug reactions (ADRs) as well as two-year RFS and OS were evaluated.</p><p><strong>Results: </strong>Median time to ANC engraftment (≥0.5 × 10<sup>3</sup>/μl: 10.0 vs. 11.0 days; P = 0.98) and PC engraftment (≥20.0 × 10<sup>3</sup>/μl: both 14.0 days; P = 0.58) was similar between groups. However, the median time to ALC recovery was significantly shorter in the calcitriol group (≥0.5 × 10<sup>3</sup>/μl: 13.0 vs. 20.0 days; P < 0.001). Moreover, ALC recovery rates on day 15 (≥0.5 × 10<sup>3</sup>/μl: 82.1% vs. 42.5%; P < 0.001) and on day 30 (≥1.0 × 10<sup>3</sup>/μl: 91.7% vs. 57.5%; P = 0.001) was significantly higher with calcitriol. WBC, PC, and HC on days 180 and 365 were not significantly different between groups. None of the OM indices were modulated by calcitriol. All the ADRs were non-serious and mild, possibly or unlikely related to the intervention. In a median of 29 months follow-up, RFS was significantly better in the calcitriol group (77.0%, SE = 7.0% vs. 59.0%, SE = 8.0%; P = 0.03), albeit the OS was not affected (87.0%, SE = 5.0% vs. 92.0%, SE = 4.0%; P = 0.72).</p><p><strong>Conclusion: </strong>Calcitriol could improve ALC recovery and RFS as a safe option post-HSCT. Graphical abstract Oral calcitriol 0.25 µg three times daily from transplantation to day 30 improved lymphocytes recovery and two-year relapse-free survival as a safe option in 80 patients of autologous hematopoietic stem cell transplantation in comparison with placebo.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"27 2","pages":"709-720"},"PeriodicalIF":3.6,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40199-019-00306-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49675388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
期刊
DARU Journal of Pharmaceutical Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1